Metamizol Stada

Metamizole Sodium, the active ingredient in Metamizol Stada, is a pyrazolone analgesic presented as an oral tablet for oral use. It is used to relieve acute pain, reduce fever, and manage postoperative discomfort in adult patients.

GNH USA supplies Metamizol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Stada, a pyrazolone analgesic, is employed in the management of pain and fever.

Acute pain: provides rapid analgesia for sudden severe pain. Fever: lowers elevated body temperature in febrile states. Post‑operative pain: controls discomfort after surgical procedures. Colic: alleviates visceral pain associated with colic episodes.

Metamizol Stada may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dizziness - Headache - Sweating - Mild hypotension

Serious or Rare Side Effects: - Agranulocytosis (severe drop in white blood cells) - Severe allergic reactions (anaphylaxis, skin rash) - Blood dyscrasias (thrombocytopenia, hemolytic anemia) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe liver injury - Renal impairment in susceptible individuals

Before prescribing Metamizol Stada, clinicians should consider several safety measures.

Assess renal function: evaluate kidney status in patients with existing impairment. Monitor blood counts: perform regular hematologic monitoring for early detection of agranulocytosis. Check for hypersensitivity: avoid use in individuals with known allergy to pyrazolones. Avoid in severe hepatic disease: use only if benefits outweigh risks. Adjust in elderly: start with the lowest effective dose and monitor closely. Store at below 25°C: keep in the original pack, protect from moisture.

Metamizol Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants: increased risk of bleeding. - Other NSAIDs: heightened gastrointestinal toxicity. - Allopurinol: elevated risk of agranulocytosis.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood‑pressure control. - Diuretics: increased potential for renal impairment. - Lithium: altered serum lithium levels, requiring monitoring.